Novo Nordisk Shares Plunge 40% on Shocking 2026 Sales Guidance Cut

Key Facts

1Novo Nordisk beat Q4 consensus on revenue and adjusted EPS.

2Shares fell nearly 40% after a shocking FY2026 sales guidance cut.

3Management guided a FY2026 sales decline of 5-13%, citing U.S. price pressure and LOE effects.

4Obesity-care grew 31%, but EBIT margin fell 290 basis points due to higher R&D and admin costs.

Novo Nordisk reported strong fourth-quarter results, beating analyst expectations for both revenue and adjusted earnings per share. However, shares of the pharmaceutical giant plummeted nearly 40% following a surprise downward revision of its 2026 financial outlook. Management now anticipates a sales decline of 5% to 13% for the 2026 fiscal year, citing significant pricing pressures in the United States and the impact of loss of exclusivity. While the company's obesity-care segment saw robust growth of 31%, overall operating margins contracted by 290 basis points due to rising research and development costs. Investors are increasingly concerned about the long-term pricing power of blockbuster drugs amid shifting regulatory landscapes. This massive sell-off reflects a major shift in market sentiment regarding the future growth trajectory of the world's leading obesity treatment provider.